Welcome to our dedicated page for Intuitive Surgical news (Ticker: ISRG), a resource for investors and traders seeking the latest updates and insights on Intuitive Surgical stock.
Intuitive Surgical Inc. (NASDAQ: ISRG), the pioneer of robotic-assisted minimally invasive surgery, provides critical updates through this comprehensive news hub. Track the latest developments surrounding the da Vinci Surgical System, regulatory milestones, and strategic initiatives shaping the future of surgical care.
This resource delivers verified press releases and financial updates essential for understanding ISRG's market position. Investors gain insights into earnings reports, partnership announcements, and technology advancements while medical professionals stay informed about clinical applications and procedural innovations.
Key content includes quarterly financial results, FDA clearances for new instruments, global expansion updates, and research collaborations advancing robotic surgery. All materials are sourced from official channels to ensure accuracy and compliance with financial disclosure standards.
Bookmark this page for real-time access to ISRG's evolving role in healthcare technology. Combine strategic awareness with operational knowledge through our curated collection of company-verified information.
Intuitive (ISRG) reported strong Q1 2025 financial results with revenue reaching $2.25 billion, up 19% year-over-year. The company's da Vinci surgical system installations grew significantly, with 367 new placements (including 147 da Vinci 5 systems) compared to 313 in Q1 2024.
Key highlights include a 17% growth in worldwide da Vinci procedures and a 15% increase in the installed base to 10,189 systems. GAAP net income rose to $698 million ($1.92 per diluted share), while non-GAAP net income reached $662 million ($1.81 per diluted share).
The company ended Q1 with $9.10 billion in cash and investments. For 2025, Intuitive projects worldwide da Vinci procedure growth of 15-17% and expects non-GAAP operating expense growth of 10-14%.
Intuitive (NASDAQ: ISRG) announced two significant studies highlighting the impact of robotic-assisted surgery (RAS) on healthcare accessibility. The first study, published in the Journal of the Society of Laparoscopic & Robotic Surgeons, examined minimally invasive surgery (MIS) deserts and found that surgeon characteristics account for nearly two-thirds of variation in MIS use.
The second study, published in Annals of Surgery Open, analyzed data from 408 U.S. hospitals between 2016-2022. Hospitals implementing RAS saw MIS rates increase from 60.5% to 65.8%, compared to minimal growth (56.1% to 57.0%) in non-RAS hospitals. The greatest improvements were observed in hernia repairs and colorectal resections.
The research demonstrates that RAS helps overcome traditional laparoscopy barriers through shorter learning curves for surgeons and improved visualization, ultimately expanding patient access to minimally invasive procedures across various demographics.
Intuitive (ISRG) has received FDA clearance for its SP SureForm 45 stapler, designed specifically for single-port robotic surgery with the da Vinci SP surgical system. The stapler features SmartFire technology that continuously monitors tissue compression, optimizing staple line integrity and reducing tissue damage risks.
The device is cleared for thoracic, colorectal, and urologic procedures in the U.S. The da Vinci SP system enables surgeons to control up to three wristed instruments and an HD 3D camera through a single access point, promoting faster patient recovery and reduced postoperative pain. The system triangulates instruments inside the body, helping prevent external instrument collisions in small surgical spaces.
Intuitive (NASDAQ: ISRG) has published two peer-reviewed studies in Surgical Endoscopy demonstrating the effectiveness of its Force Feedback technology in the da Vinci 5 surgical system. The first study, led by Dr. Michael M. Awad, showed that the technology can reduce force on tissue by up to 43% across all surgeon experience levels.
The second study, led by Dr. Andrew J. Hung, revealed that Force Feedback technology significantly improves novice surgeon performance, reducing tissue trauma and errors during suturing. The research involved 28 surgeons in the first study and 29 novice surgeons in the second study, all conducted in pre-clinical settings using tissue models.
The technology is currently available in U.S. hospitals, with plans for expanded availability through 2025 and beyond.
Intuitive (NASDAQ:ISRG) has announced a $45 million donation to the Intuitive Foundation, bringing total contributions to over $170 million since 2018. The Foundation focuses on reducing global disease burden through philanthropy, research, and education for better patient outcomes.
In 2024, the Foundation matched employee donations with over $7 million supporting 2,000+ causes, provided $6 million in research grants and surgical fellowships, and contributed $3 million to the Surgical Education Learners Forum. Key programs include the Global Surgical Training Challenge, supporting FIRST Robotics teams globally, and the Surgical Education Learners Forum (SELF), which develops free training modules for clinicians in low-resource settings.
Intuitive (ISRG) reported strong Q4 2024 financial results with revenue reaching $2.41 billion, up 25% from Q4 2023. The company's worldwide da Vinci procedures grew 18% year-over-year, while system placements increased to 493 units, including 174 da Vinci 5 systems. The installed base expanded to 9,902 systems, marking a 15% increase from the previous year.
GAAP net income rose to $686 million ($1.88 per diluted share), compared to $606 million ($1.69 per diluted share) in Q4 2023. Non-GAAP net income reached $805 million ($2.21 per diluted share). The company ended Q4 with $8.83 billion in cash and investments.
For 2025 outlook, Intuitive expects worldwide da Vinci procedures to grow 13-16%, with non-GAAP gross profit margin projected between 67-68% and operating expense growth of 10-15%.
Intuitive (NASDAQ:ISRG) has announced plans to establish a direct presence in Italy, Spain, Portugal, Malta, and San Marino through the acquisition of da Vinci and Ion distribution businesses in these regions. The company has entered into agreements with current distributors ab medica, Abex, Excelencia Robotica, and their affiliates.
The transaction is subject to regulatory approvals and is expected to close in 2026. Upon closure, the distribution businesses will be fully integrated into Intuitive's European commercial and marketing organization, led by Senior VP and General Manager Dirk Barten. The move aims to deepen understanding of customer needs and expand access to minimally invasive care in these markets.
Intuitive (ISRG) reported strong preliminary Q4 and full-year 2024 results. Q4 revenue reached $2.41 billion, up 25% year-over-year, while full-year 2024 revenue grew 17% to $8.35 billion. The company placed 493 da Vinci surgical systems in Q4 2024, including 174 da Vinci 5 systems, marking a 19% increase from Q4 2023.
Worldwide da Vinci procedures grew approximately 18% in Q4 and 17% for the full year 2024, reaching approximately 2,683,000 procedures. Growth was driven by a 19% increase in U.S. general surgery procedures and 23% growth in procedures outside the U.S. The company projects worldwide da Vinci procedures to increase 13-16% in 2025.
Q4 instruments and accessories revenue increased 23% to $1.41 billion, while systems revenue grew 36% to $655 million. The company noted no significant COVID-19 disruptions during 2024.
Intuitive (NASDAQ:ISRG) announced three executive leadership promotions to support its global growth strategy. Henry Charlton has been promoted to Executive Vice President and Chief Commercial and Marketing Officer, bringing 21 years of experience across various leadership roles. Gary Loeb has been elevated to Executive Vice President and Chief Legal and Compliance Officer, having joined in 2022 as SVP and General Counsel. Jamie Samath has been promoted to Executive Vice President, Chief Financial Officer and Enterprise Technology Leader, expanding his role since joining in 2013.
These promotions aim to strengthen Intuitive's leadership team as it continues its mission in advancing minimally invasive care. The company, which pioneered robotic-assisted surgery with its da Vinci system, has facilitated over 15 million procedures globally and trained more than 76,000 surgeons worldwide.
A comprehensive meta-analysis published in Annals of Surgery has demonstrated significant benefits of da Vinci robotic surgery compared to laparoscopic and open surgical approaches. The study analyzed 230 studies from 22 countries over 12 years, including randomized controlled trials, prospective studies, and database reviews.
Key findings show that da Vinci robotic cases were 56% less likely to convert to open surgery versus laparoscopy, experienced 21% fewer blood transfusions versus laparoscopy and 75% versus open, and had 10% fewer 30-day postop complications versus laparoscopy and 44% versus open. Patients also experienced shorter hospital stays, though operative times were longer than both traditional approaches.
